Overview

Lenvatinib and Pembrolizumab Simultaneous Combination Study

Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of the use of pembrolizumab in combination with lenvatinib.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center Hospital East
Collaborators:
Eisai Co., Ltd.
Merck Sharp & Dohme Corp.
Treatments:
Lenvatinib
Pembrolizumab